MedTrace Logo

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

NCT00651456 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2023-03-13

No results posted yet for this study

Summary

Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.

Conditions

Interventions

DRUG

Standard Chemotherapy (Pemetrexed and Cisplatin)

* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles) * Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)

DRUG

Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab

* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles) * Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles) * Bevacizumab 15 mg/kg D1 (D1=D22, until progression)

Sponsors & Collaborators

  • University Hospital, Caen

    collaborator OTHER

  • Groupe Francais De Pneumo-Cancerologie

    collaborator OTHER

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Gilles Robinet, Dr · GFPC

  • Arnaud Scherpereel, Dr · Intergroupe Francophone de Cancerologie Thoracique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2015-01-31
Completion
2016-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651456 on ClinicalTrials.gov